Tae Heon Kim1, Yoon-Tae Kang2, Young-Ho Cho2, Jeong Hoon Kim3, Byong Chang Jeong4, Seong Il Seo4, Seong Soo Jeon4, Hyun Moo Lee4. 1. Department of Urology, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea. 2. Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea. 3. Department of Molecular Biology, Samsung Advanced Institute for Health Science and Technology (SAIHST), Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 4. Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Abstract
INTRODUCTION: The aim of this study was to detect circulating tumour cells (CTCs) in patients with advanced renal cell carcinoma (RCC) using a novel CTC detection platform. Furthermore, we evaluated the clinical outcomes associated with a CTC-positive status. METHODS: A total of 34 patients with advanced RCC (stage III or IV) were prospectively enrolled, and 104 peripheral blood samples were analyzed for the presence of CTCs at various time points. CTCs were isolated using a tapered-slit filter, which captures CTCs based on size and deformability. The presence of CTCs was confirmed using both staining and morphological criteria. CTC status was then correlated with clinical characteristics and survival outcomes. RESULTS: CTCs were detected in 62% of patients during the pre-treatment period, and the median CTC count was 2 (interquartile range 1-3). During the followup period, CTCs were detected in 56% (18/32), 65% (20/31), and 41% (7/17) of patients at one week, one month, and three months after treatment, respectively. Overall, CTCs were found in 57.9% (66/114) of blood samples in the range of 1-7 cells. Although no statistical significance was found, CTC detection in patients with stage IV disease was more common than in patients with stage III disease (68.4% vs. 53.3%). Two-year progression-free survival and cancer-specific survival tended to be lower in CTC-positive patients compared with CTC-negative patients. CONCLUSIONS: The tapered-slit filter is an efficient technique to detect CTCs in advanced RCC.
INTRODUCTION: The aim of this study was to detect circulating tumour cells (CTCs) in patients with advanced renal cell carcinoma (RCC) using a novel CTC detection platform. Furthermore, we evaluated the clinical outcomes associated with a CTC-positive status. METHODS: A total of 34 patients with advanced RCC (stage III or IV) were prospectively enrolled, and 104 peripheral blood samples were analyzed for the presence of CTCs at various time points. CTCs were isolated using a tapered-slit filter, which captures CTCs based on size and deformability. The presence of CTCs was confirmed using both staining and morphological criteria. CTC status was then correlated with clinical characteristics and survival outcomes. RESULTS: CTCs were detected in 62% of patients during the pre-treatment period, and the median CTC count was 2 (interquartile range 1-3). During the followup period, CTCs were detected in 56% (18/32), 65% (20/31), and 41% (7/17) of patients at one week, one month, and three months after treatment, respectively. Overall, CTCs were found in 57.9% (66/114) of blood samples in the range of 1-7 cells. Although no statistical significance was found, CTC detection in patients with stage IV disease was more common than in patients with stage III disease (68.4% vs. 53.3%). Two-year progression-free survival and cancer-specific survival tended to be lower in CTC-positive patients compared with CTC-negative patients. CONCLUSIONS: The tapered-slit filter is an efficient technique to detect CTCs in advanced RCC.
Authors: Daniel L Adams; Steingrimur Stefansson; Christian Haudenschild; Stuart S Martin; Monica Charpentier; Saranya Chumsri; Massimo Cristofanilli; Cha-Mei Tang; R Katherine Alpaugh Journal: Cytometry A Date: 2014-12-16 Impact factor: 4.355
Authors: Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; Jeri Matera; M Craig Miller; James M Reuben; Gerald V Doyle; W Jeffrey Allard; Leon W M M Terstappen; Daniel F Hayes Journal: N Engl J Med Date: 2004-08-19 Impact factor: 91.245
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: R S Bhatt; A J Zurita; A O'Neill; A Norden-Zfoni; L Zhang; H K Wu; P Y Wen; D George; V P Sukhatme; M B Atkins; J V Heymach Journal: Br J Cancer Date: 2011-06-14 Impact factor: 7.640
Authors: Sergei Kusmartsev; Zhen Su; Axel Heiser; Jens Dannull; Evgeniy Eruslanov; Hubert Kübler; Donna Yancey; Philip Dahm; Johannes Vieweg Journal: Clin Cancer Res Date: 2008-12-15 Impact factor: 12.531
Authors: Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan Journal: Clin Cancer Res Date: 2008-10-01 Impact factor: 12.531
Authors: Wenxin Xu; Mäneka Puligandla; Brian Halbert; Naomi B Haas; Keith T Flaherty; Robert G Uzzo; Janice P Dutcher; Robert S DiPaola; Venkata Sabbisetti; Rupal S Bhatt Journal: Clin Cancer Res Date: 2021-04-08 Impact factor: 12.531